ITGAX and neoplasm: This study revealed that after two weeks of tumor‐bearing, a higher percentage of spleen antigen‐presenting cells (CD11c+, HLA+, CD80+, and CD11b+) was observed in the iPSC+CpG group (Fig 3a and b).